AbbV Dividend Increase 2024: What to Expect

AbbVie has a history of increasing its dividend, with a streak of 52 consecutive quarterly dividend payments, dating back to 2013.

The company's commitment to returning value to shareholders is evident in its consistent dividend growth.

In recent years, AbbVie has shown a trend of increasing its dividend payout by 10% or more annually.

This trend is expected to continue in 2024.

Investors can expect AbbVie to continue its dividend growth streak in 2024, with a possible increase in the range of 8-12% based on historical trends.

For another approach, see: Trend Line (technical Analysis)

AbbVie has a solid track record of paying dividends with very little fluctuation.

The company has a sustained record of paying dividends with very little fluctuation. Since 2015, the dividend has gone from $1.68 total annually to $6.56.

This means that it has been growing its distributions at 15% per annum over that time.

It is good to see that there has been strong dividend growth, and that there haven't been any cuts for a long time.

Expand your knowledge: 4 Little Known Truths about Equity Release

AbbVie's dividend growth is a mixed bag. The company has grown earnings per share at a decent rate of 5.7% per year over the past five years.

The good news is that AbbVie's free cash flows comfortably cover its dividend payments, which is a plus for dividend investors. Generally, we think cash is more important than accounting measures of profit, so this is a good sign.

However, AbbVie's dividend payout ratio is estimated to be around 70% if the dividend continues along recent trends. This could limit future growth, as a significant portion of earnings is being paid out to shareholders.

Looking ahead, AbbVie's earnings per share is forecast to rise exponentially over the next year, which could support the dividend payments. But, this growth may not be enough to justify the current dividend level.

Overall, AbbVie's dividend growth is not as strong as some investors might hope for, and there are concerns about the sustainability of the current dividend level.

You might like: Fiscal Theory of the Price Level

AbbVie is a strong dividend payer, having raised its payouts for 52 consecutive years.

The company offers a quarterly dividend of $1.64 per share and has a dividend yield of 3.55% as of May 13.

AbbVie's focus on innovation and chronic disease treatments has led to impressive financial results, with revenue reaching $13.3 billion in the first quarter of 2025.

This marks an 8.3% year-over-year increase and surpasses expectations by $422 million.

The company's immunology portfolio, particularly from Skyrizi and Rinvoq, has helped balance the anticipated decline in Humira sales.

AbbVie also saw solid performance in neuroscience and oncology, with Elahere generating $179 million globally.

This growth is boosted by favorable results from the MIRASOL trial, which showed Elahere significantly outperformed chemotherapy in ovarian cancer treatment.

AbbVie continues to strengthen its pipeline through strategic acquisitions and partnerships.

The company has acquired ImmunoGen to secure Elahere, purchased Nimble Therapeutics to bolster its autoimmune offerings, and entered a licensing deal with Gubra to advance in the obesity drug market.

AbbVie has a significant war chest of cash, equal to nearly one-third of its entire market cap.

This financial stability provides a solid foundation for the company's future growth and dividend payments.